Brad Hively Sells 298,853 Shares of Oncology Institute (NASDAQ:STLN) Stock

Key Points

• Director Brad Hively sold 298,853 Oncology Institute shares at an average price of $6.51, generating approximately $1.95 million. The Rule 10b5-1 plan transaction reduced his stake by 42.04% to 411,976 shares.
• Oncology Institute shares fell 5.3% to $6.13 in Monday trading. The company reported a quarterly loss of $0.08 per share but exceeded revenue expectations with $161.28 million versus the $152.80 million consensus estimate.
• The stock carries a consensus “Sell” rating, while AXQ Capital recently initiated a 22,460-share position; institutional investors collectively own 36.86% of the company.

Oncology Institute, Inc. (NASDAQ:STLN - Get Free Report) Director Brad Hively sold 298,853 shares of the firm's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the transaction, the director owned 411,976 shares of the company's stock, valued at approximately $2,681,963.76. This represents a 42.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Stock Down 5.3%

Shares of STLN traded down $0.34 during midday trading on Monday, hitting $6.13. 1,228,983 shares of the company traded hands, compared to its average volume of 1,888,221. Oncology Institute, Inc. has a one year low of $2.32 and a one year high of $7.05. The stock has a market cap of $605.89 million, a PE ratio of -20.43 and a beta of 0.39.

Oncology Institute (NASDAQ:STLN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $161.28 million for the quarter, compared to the consensus estimate of $152.80 million. Analysts expect that Oncology Institute, Inc. will post -0.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings assumed coverage on shares of Oncology Institute in a research report on Thursday, August 6th. They set a "sell (d-)" rating for the company. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of "Sell".

Institutional Trading of Oncology Institute

An institutional investor recently bought a new position in Oncology Institute stock. AXQ Capital LP purchased a new position in Oncology Institute, Inc. (NASDAQ:STLN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,460 shares of the company's stock, valued at approximately $122,000. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Oncology Institute Company Profile

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company's business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source